API CAS 64485-93-4 Cefotaxime Sodium Powder Material Cefotaxime Sodium Powder Cefotaxime Sodium

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Cefotaxime Sodium
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Shelf Life: 2 Years
• Mf: C16h16n5nao7s2
• MW: 477.442
• Density: 1.8 g/cm3
• Melting Point: 162-163 °c(Lit.)
• Refractive Index: 61 ° (C=1, H2O)
• Specific Rotation: D20 +55±2° (C = 0.8 in Water)
• Psa: 229.88000
• Logp: -1.04720
• Signal Word: Danger
• Hazard Statements: H317-H334
• Cautionary Statement: P261-P280-P284-P304 + P340-P342 + P311
• Rtecs: Xi0250000
• Dangerous Goods Sign: Xn
• Dangerous Goods Shipping Code: Nonh for All Modes of Transport
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• HS Code: 29419000
• Production Capacity: 1000kg/Month

Product Description

API CAS 64485-93-4 Cefotaxime Sodium powder Material Cefotaxime sodium powder Cefotaxime sodium

Product Description

Product Details

CAS No:	64485-93-4
molecular formula	C16H16N5NaO7S2
Place of Origin:	China
molecular weight	477.45
EINECS	264-915-9
Form	Powder

Cefotaxime sodium is a third-generation semi-synthetic cephalosporin, which is not as effective against gram-positive bacteria as cefazolin. Enterococci are resistant to this product, ineffective against penicillin-resistant pneumococci, and gram-negative. The bacteria have strong bactericidal activity, and the antibacterial effect on Escherichia coli, Bacillus influenzae, Pneumococcus, Proteus mirabilis, and Salmonella is stronger than that of cefoperazone, weak or resistant to Bacteroides fragilis, Pseudomonas aeruginosa, sewerage Enterobacteriaceae are not sensitive to this product.

Application&Function

Function
Treatment of infections of lower respiratory tract including pneumonia, urinary tract, skin and skin structures, bone and joints; treatment of bacteremia/septicemia, CNS infections, intra-abdominal infections including peritonitis, gynecological infections including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by susceptible strains of specific microorganisms; perioperative prophylaxis.
 

Specification